Scholarlink

<p>Inflammation plays a pivotal role in acute ischemic stroke (AIS), with neutrophil granulocytes acting as major contributors to the post-stroke immune response. Upon degranulation, neutrophils release matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO), both of which may influence functional outcomes following AIS. The aim of this study was to investigate the association between systemic levels of MMP-9 and MPO, functional outcome, and neutrophil counts in patients with moderate to severe AIS, with a focus on their pathophysiological relevance rather than standalone prognostic performance. This prospective single-center cohort study included patients with moderate to severe AIS in the anterior circulation (NIHSS score ≥ 6 points and /or indication for mechanical recanalization). Venous blood was sampled in order to assess plasma concentrations of MMP-9 via zymography as well as MPO plasma levels via ELISA. Furthermore, differential blood count was determined simultaneously to venous biomarker sampling. Poor outcome was defined as mRS score ≥ 3. Uni- and multivariable regression analyses were performed. Between 07/2020 and 09/2022 a total of 279 patients with blood samples taken up to 48&#xa0;h after symptom onset with a median NIHSS score of 13 and a median age of 79 were included. Of these patients, 81.0% underwent mechanical recanalization and 42.7% received systemic thrombolytic therapy. Systemic MMP-9 and MPO plasma levels were significantly higher in patients with poor functional outcome compared to patients with good functional outcome at 3-months (MMP-9: 359.1 vs. 303.5 ng/ml, <i>p</i> = 0.0006; MPO: 27.0 vs. 19.2 ng/ml, <i>p</i> = 0.0010). Both biomarkers were associated with a poor outcome in unadjusted analyses [MMP-9: unadjusted OR = 15.63 (95% CI: 3.54-80.69), <i>p</i> = 0.0005; MPO: unadjusted OR = 4.02 (95% CI: 1.84-9.21), <i>p</i> = 0.0007]. In addition, MMP-9 and MPO concentrations correlated with neutrophil counts (MMP-9: <i>r</i> = 0.39, <i>p</i> &lt; 0.0001; MPO: <i>r</i> = 0.31, <i>p</i> &lt; 0.0001). In conclusion, systemic MMP-9 and MPO plasma concentrations are associated with functional outcome in patients with moderate to severe AIS and reflect neutrophil-driven inflammatory processes. Their value appears to lie in complementing established clinical predictors rather than serving as independent prognostic markers.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Associations of plasma MMP-9 and MPO with functional outcome in moderate to severe acute ischemic stroke

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月10日

查看全文
  • Vivian Vogt,
  • Christoph Vollmuth,
  • Guido Stoll,
  • Felipe A. Montellano,
  • Peter U. Heuschmann,
  • Alexander M. Kollikowski,
  • Mirko Pham,
  • Karl Georg Haeusler,
  • Hermann Neugebauer,
  • Michael K. Schuhmann

摘要

Inflammation plays a pivotal role in acute ischemic stroke (AIS), with neutrophil granulocytes acting as major contributors to the post-stroke immune response. Upon degranulation, neutrophils release matrix metalloproteinase-9 (MMP-9) and myeloperoxidase (MPO), both of which may influence functional outcomes following AIS. The aim of this study was to investigate the association between systemic levels of MMP-9 and MPO, functional outcome, and neutrophil counts in patients with moderate to severe AIS, with a focus on their pathophysiological relevance rather than standalone prognostic performance. This prospective single-center cohort study included patients with moderate to severe AIS in the anterior circulation (NIHSS score ≥ 6 points and /or indication for mechanical recanalization). Venous blood was sampled in order to assess plasma concentrations of MMP-9 via zymography as well as MPO plasma levels via ELISA. Furthermore, differential blood count was determined simultaneously to venous biomarker sampling. Poor outcome was defined as mRS score ≥ 3. Uni- and multivariable regression analyses were performed. Between 07/2020 and 09/2022 a total of 279 patients with blood samples taken up to 48 h after symptom onset with a median NIHSS score of 13 and a median age of 79 were included. Of these patients, 81.0% underwent mechanical recanalization and 42.7% received systemic thrombolytic therapy. Systemic MMP-9 and MPO plasma levels were significantly higher in patients with poor functional outcome compared to patients with good functional outcome at 3-months (MMP-9: 359.1 vs. 303.5 ng/ml, p = 0.0006; MPO: 27.0 vs. 19.2 ng/ml, p = 0.0010). Both biomarkers were associated with a poor outcome in unadjusted analyses [MMP-9: unadjusted OR = 15.63 (95% CI: 3.54-80.69), p = 0.0005; MPO: unadjusted OR = 4.02 (95% CI: 1.84-9.21), p = 0.0007]. In addition, MMP-9 and MPO concentrations correlated with neutrophil counts (MMP-9: r = 0.39, p < 0.0001; MPO: r = 0.31, p < 0.0001). In conclusion, systemic MMP-9 and MPO plasma concentrations are associated with functional outcome in patients with moderate to severe AIS and reflect neutrophil-driven inflammatory processes. Their value appears to lie in complementing established clinical predictors rather than serving as independent prognostic markers.